RELEVIUM

RELEVIUM

Pancreatic cancer has the lowest survival rate among other cancers and is responsible for 95,000 deaths every year in the EU. Its treatment is usually palliative, aiming at slowing tumor progression and at symptom management. The ultimate purpose of this project is to improve the quality of life for advanced pancreatic cancer patients with the support of state-of-the-art technology.

MCS Data Labs succeeded in its pitch to deepen its technology innovation competence in oncology. Being part of some oncology research and innovation projects, the company is now also a consortium member in the EU-funded Horizon Europe action titled ‘Improving quality of life of advanced pancreatic cancer patients through an AI-guided multimodal intervention, combining pain and cachexia management, nutrition and physical activity’, or short: RELEVIUM

The EUR 6 million project led by the University Clinic of Johannes Gutenberg University Mainz (Germany) is based on the hypothesis that quality of life of advanced pancreatic cancer patients can be improved through highly personalized nutrition, physical activity and pain management, in addition to chemotherapy treatment. On the technical side this shall be achieved by empowring patients with digital tools for monitoring, patient-doctor communication and self-management

MCS’ main responsibility is in the development of a multi-sensor wearable device (‘smart watch’) and an innovative remote ultrasound patch. The company also has supportive roles in the development of IOS/ Android mobile web app’s, web applications and a pain index.

This project has received funding from the European Union’s Horizon research and innovation program under grant agreement No 101057821
Back To Top